TBD Meeting (5392-20)

“Kidney disease is the most common chronic disease in the United States and the world, and the incidence is on the rise,” said Kim Zuber, PA-C, executive director of the American Academy of Nephrology PAs and outreach chair for the National Kidney Foundation in St. Petersburg, Fla.

Kidney disease also is an expensive problem that accounts for approximately 20% of the Medicare budget in the United States, she said in a virtual presentation at the Metabolic & Endocrine Disease Summit by Global Academy for Medical Education.

“It’s important that we know how to identify it and how to slow the progression if possible, and what to do when we can no longer control the disease,” she said.

Notably, the rate of growth for kidney disease is highest among adults aged 20-45 years, said Ms. Zuber. “That is the group who will live for many years with kidney disease,” but should be in their peak years of working and earning. “That is the group we do not want to develop chronic diseases.”

“Look for kidney disease. It’s not always on the chart; it is often missed because people don’t think of it,” Ms. Zuber said. Anyone over 60 years has likely lost some kidney function. Other risk factors include minority/ethnicity, hypertension or cardiovascular disease, diabetes, and a family history of kidney disease.

Women are more likely to develop chronic kidney disease (CKD), but less likely to go on dialysis, said Ms. Zuber. “What I find fascinating is that a history of oophorectomy” increases risk. Other less obvious risk factors in a medical history that should prompt a kidney disease screening include mothers who drank during pregnancy, individuals with a history of acute kidney disease, lupus, sarcoid, amyloid, gout, or other autoimmune conditions, as well as a history of kidney stones of cancer. Kidney donors or transplant recipients are at increased risk, as are smokers, soda drinkers, and heavy salt users.

CKD is missed by many health care providers, Ms. Zuber said. For example, she cited data from more than 270,000 veterans treated at a Veterans Affairs hospital in Texas, which suggested that the likelihood of adding CKD to a patient’s diagnosis was 43.7% even if lab results confirmed CKD.
 

Find the patients

There are many formulas for defining kidney function, Ms. Zuber said. The estimation of creatinine clearance (eCrCl) and estimated glomerular filtration rate (eGFR) are among them. The most common definition is to calculate eGFR using the CKD-EPI formula. Cystatin C is more exact, but it is not standardized, so a lab in one state does not use the same formula as one in another state.

Overall, all these formulas are plus or minus 30%. “It is an estimate,” she said. Within the stages of CKD, “what we know is that, if you have a high GFR, that’s good, but patients who are losing albumin are at increased risk for CKD.” The albumin is more of a risk factor for CKD than GFR, so the GFR test used doesn’t make much difference, whereas, “if you have a lot of albumin in your urine, you are going downhill,” she said.

Normally, everyone loses kidney function with age, Ms. Zuber said. Starting at age 30, individuals lose about 1 mL/min per year in measures of GFR, however, this progression is more rapid among those with CKD, so “we need to find those people who are progressing more quickly than normal.”

The way to identify the high-risk patients is albumin, Ms. Zuber said. Health care providers need to test the urine and check albumin for high levels of albumin loss through urine, and many providers simply don’t routinely conduct urine tests for patients with other CKD risk factors such as diabetes or hypertension.

Albuminuria levels of 2,000 mg/g are the most concerning, and a urine-albumin-to-creatinine ratio (UACR) test is the most effective tool to monitor kidney function, Ms. Zuber said.

She recommends ordering a UACR test at least once a year to monitor kidney loss in all patients with hypertension, diabetes, lupus, and other risk factors including race and a history of acute kidney injury.
 

Keep them healthy

Managing patients with chronic kidney disease includes attention to several categories: hypertension, diabetes, obesity, and cardiovascular disease, and mental health, Ms. Zuber said.

“If hypertension doesn’t cause your CKD, your CKD will cause hypertension,” she said. The goal for patients with CKD is a target systolic blood pressure less than 120 mm Hg. “As kidney disease progresses, hypertension becomes harder to control,” she added. Lifestyle changes including exercise, low-fat diet, limited use of salt, weight loss if needed, and stress reduction strategies can help.

For patients with diabetes and CKD, work towards a target hemoglobin A1c of 7.0 for early CKD, and of 8% for stage 4/5 or for older patients with multiple comorbidities, Ms. Zuber said. All types of insulin are safe for CKD patients. “Kidney function declines at twice the normal rate for diabetes patients; however, SGLT2 inhibitors are very renoprotective. You may not see a drop in A1c, but you are protecting the kidney.”

For patients with obesity and CKD, data show that bariatric surgery (gastric bypass) lowers mortality in diabetes and also protects the heart and kidneys, said Ms. Zuber. Overall, central obesity increases CKD risk independent of any other risk factors, but losing weight, either by surgery or diet/lifestyle, helps save the kidneys.

Cardiovascular disease is the cause of death for more than 70% of kidney disease patients, Ms. Zuber said. CKD patients “are two to three times more likely to have atrial fibrillation, so take the time to listen with that stethoscope,” she added, also emphasizing the importance of statins for all CKD and diabetes patients, and decreasing smoking. In addition, “managing metabolic acidosis slows the loss of kidney function and protects the heart.”

Additional pearls for managing chronic kidney disease include paying attention to a patient’s mental health; depression occurs in roughly 25%-47% of CKD patients, and anxiety in approximately 27%, said Ms. Zuber. Depression “is believed to be the most common psychiatric disorder in patients with end stage renal disease,” and data suggest that managing depression can help improve survival in CKD patients.

Global Academy and this news organization are owned by the same parent company. Ms. Zuber had no financial conflicts to disclose.

“Kidney disease is the most common chronic disease in the United States and the world, and the incidence is on the rise,” said Kim Zuber, PA-C, executive director of the American Academy of Nephrology PAs and outreach chair for the National Kidney Foundation in St. Petersburg, Fla.

Kidney disease also is an expensive problem that accounts for approximately 20% of the Medicare budget in the United States, she said in a virtual presentation at the Metabolic & Endocrine Disease Summit by Global Academy for Medical Education.

“It’s important that we know how to identify it and how to slow the progression if possible, and what to do when we can no longer control the disease,” she said.

Notably, the rate of growth for kidney disease is highest among adults aged 20-45 years, said Ms. Zuber. “That is the group who will live for many years with kidney disease,” but should be in their peak years of working and earning. “That is the group we do not want to develop chronic diseases.”

“Look for kidney disease. It’s not always on the chart; it is often missed because people don’t think of it,” Ms. Zuber said. Anyone over 60 years has likely lost some kidney function. Other risk factors include minority/ethnicity, hypertension or cardiovascular disease, diabetes, and a family history of kidney disease.

Women are more likely to develop chronic kidney disease (CKD), but less likely to go on dialysis, said Ms. Zuber. “What I find fascinating is that a history of oophorectomy” increases risk. Other less obvious risk factors in a medical history that should prompt a kidney disease screening include mothers who drank during pregnancy, individuals with a history of acute kidney disease, lupus, sarcoid, amyloid, gout, or other autoimmune conditions, as well as a history of kidney stones of cancer. Kidney donors or transplant recipients are at increased risk, as are smokers, soda drinkers, and heavy salt users.

CKD is missed by many health care providers, Ms. Zuber said. For example, she cited data from more than 270,000 veterans treated at a Veterans Affairs hospital in Texas, which suggested that the likelihood of adding CKD to a patient’s diagnosis was 43.7% even if lab results confirmed CKD.
 

Find the patients

There are many formulas for defining kidney function, Ms. Zuber said. The estimation of creatinine clearance (eCrCl) and estimated glomerular filtration rate (eGFR) are among them. The most common definition is to calculate eGFR using the CKD-EPI formula. Cystatin C is more exact, but it is not standardized, so a lab in one state does not use the same formula as one in another state.

Overall, all these formulas are plus or minus 30%. “It is an estimate,” she said. Within the stages of CKD, “what we know is that, if you have a high GFR, that’s good, but patients who are losing albumin are at increased risk for CKD.” The albumin is more of a risk factor for CKD than GFR, so the GFR test used doesn’t make much difference, whereas, “if you have a lot of albumin in your urine, you are going downhill,” she said.

Normally, everyone loses kidney function with age, Ms. Zuber said. Starting at age 30, individuals lose about 1 mL/min per year in measures of GFR, however, this progression is more rapid among those with CKD, so “we need to find those people who are progressing more quickly than normal.”

The way to identify the high-risk patients is albumin, Ms. Zuber said. Health care providers need to test the urine and check albumin for high levels of albumin loss through urine, and many providers simply don’t routinely conduct urine tests for patients with other CKD risk factors such as diabetes or hypertension.

Albuminuria levels of 2,000 mg/g are the most concerning, and a urine-albumin-to-creatinine ratio (UACR) test is the most effective tool to monitor kidney function, Ms. Zuber said.

She recommends ordering a UACR test at least once a year to monitor kidney loss in all patients with hypertension, diabetes, lupus, and other risk factors including race and a history of acute kidney injury.
 

Keep them healthy

Managing patients with chronic kidney disease includes attention to several categories: hypertension, diabetes, obesity, and cardiovascular disease, and mental health, Ms. Zuber said.

“If hypertension doesn’t cause your CKD, your CKD will cause hypertension,” she said. The goal for patients with CKD is a target systolic blood pressure less than 120 mm Hg. “As kidney disease progresses, hypertension becomes harder to control,” she added. Lifestyle changes including exercise, low-fat diet, limited use of salt, weight loss if needed, and stress reduction strategies can help.

For patients with diabetes and CKD, work towards a target hemoglobin A1c of 7.0 for early CKD, and of 8% for stage 4/5 or for older patients with multiple comorbidities, Ms. Zuber said. All types of insulin are safe for CKD patients. “Kidney function declines at twice the normal rate for diabetes patients; however, SGLT2 inhibitors are very renoprotective. You may not see a drop in A1c, but you are protecting the kidney.”

For patients with obesity and CKD, data show that bariatric surgery (gastric bypass) lowers mortality in diabetes and also protects the heart and kidneys, said Ms. Zuber. Overall, central obesity increases CKD risk independent of any other risk factors, but losing weight, either by surgery or diet/lifestyle, helps save the kidneys.

Cardiovascular disease is the cause of death for more than 70% of kidney disease patients, Ms. Zuber said. CKD patients “are two to three times more likely to have atrial fibrillation, so take the time to listen with that stethoscope,” she added, also emphasizing the importance of statins for all CKD and diabetes patients, and decreasing smoking. In addition, “managing metabolic acidosis slows the loss of kidney function and protects the heart.”

Additional pearls for managing chronic kidney disease include paying attention to a patient’s mental health; depression occurs in roughly 25%-47% of CKD patients, and anxiety in approximately 27%, said Ms. Zuber. Depression “is believed to be the most common psychiatric disorder in patients with end stage renal disease,” and data suggest that managing depression can help improve survival in CKD patients.

Global Academy and this news organization are owned by the same parent company. Ms. Zuber had no financial conflicts to disclose.

“Kidney disease is the most common chronic disease in the United States and the world, and the incidence is on the rise,” said Kim Zuber, PA-C, executive director of the American Academy of Nephrology PAs and outreach chair for the National Kidney Foundation in St. Petersburg, Fla.

Kidney disease also is an expensive problem that accounts for approximately 20% of the Medicare budget in the United States, she said in a virtual presentation at the Metabolic & Endocrine Disease Summit by Global Academy for Medical Education.

“It’s important that we know how to identify it and how to slow the progression if possible, and what to do when we can no longer control the disease,” she said.

Notably, the rate of growth for kidney disease is highest among adults aged 20-45 years, said Ms. Zuber. “That is the group who will live for many years with kidney disease,” but should be in their peak years of working and earning. “That is the group we do not want to develop chronic diseases.”

“Look for kidney disease. It’s not always on the chart; it is often missed because people don’t think of it,” Ms. Zuber said. Anyone over 60 years has likely lost some kidney function. Other risk factors include minority/ethnicity, hypertension or cardiovascular disease, diabetes, and a family history of kidney disease.

Women are more likely to develop chronic kidney disease (CKD), but less likely to go on dialysis, said Ms. Zuber. “What I find fascinating is that a history of oophorectomy” increases risk. Other less obvious risk factors in a medical history that should prompt a kidney disease screening include mothers who drank during pregnancy, individuals with a history of acute kidney disease, lupus, sarcoid, amyloid, gout, or other autoimmune conditions, as well as a history of kidney stones of cancer. Kidney donors or transplant recipients are at increased risk, as are smokers, soda drinkers, and heavy salt users.

CKD is missed by many health care providers, Ms. Zuber said. For example, she cited data from more than 270,000 veterans treated at a Veterans Affairs hospital in Texas, which suggested that the likelihood of adding CKD to a patient’s diagnosis was 43.7% even if lab results confirmed CKD.
 

Find the patients

There are many formulas for defining kidney function, Ms. Zuber said. The estimation of creatinine clearance (eCrCl) and estimated glomerular filtration rate (eGFR) are among them. The most common definition is to calculate eGFR using the CKD-EPI formula. Cystatin C is more exact, but it is not standardized, so a lab in one state does not use the same formula as one in another state.

Overall, all these formulas are plus or minus 30%. “It is an estimate,” she said. Within the stages of CKD, “what we know is that, if you have a high GFR, that’s good, but patients who are losing albumin are at increased risk for CKD.” The albumin is more of a risk factor for CKD than GFR, so the GFR test used doesn’t make much difference, whereas, “if you have a lot of albumin in your urine, you are going downhill,” she said.

Normally, everyone loses kidney function with age, Ms. Zuber said. Starting at age 30, individuals lose about 1 mL/min per year in measures of GFR, however, this progression is more rapid among those with CKD, so “we need to find those people who are progressing more quickly than normal.”

The way to identify the high-risk patients is albumin, Ms. Zuber said. Health care providers need to test the urine and check albumin for high levels of albumin loss through urine, and many providers simply don’t routinely conduct urine tests for patients with other CKD risk factors such as diabetes or hypertension.

Albuminuria levels of 2,000 mg/g are the most concerning, and a urine-albumin-to-creatinine ratio (UACR) test is the most effective tool to monitor kidney function, Ms. Zuber said.

She recommends ordering a UACR test at least once a year to monitor kidney loss in all patients with hypertension, diabetes, lupus, and other risk factors including race and a history of acute kidney injury.
 

Keep them healthy

Managing patients with chronic kidney disease includes attention to several categories: hypertension, diabetes, obesity, and cardiovascular disease, and mental health, Ms. Zuber said.

“If hypertension doesn’t cause your CKD, your CKD will cause hypertension,” she said. The goal for patients with CKD is a target systolic blood pressure less than 120 mm Hg. “As kidney disease progresses, hypertension becomes harder to control,” she added. Lifestyle changes including exercise, low-fat diet, limited use of salt, weight loss if needed, and stress reduction strategies can help.

For patients with diabetes and CKD, work towards a target hemoglobin A1c of 7.0 for early CKD, and of 8% for stage 4/5 or for older patients with multiple comorbidities, Ms. Zuber said. All types of insulin are safe for CKD patients. “Kidney function declines at twice the normal rate for diabetes patients; however, SGLT2 inhibitors are very renoprotective. You may not see a drop in A1c, but you are protecting the kidney.”

For patients with obesity and CKD, data show that bariatric surgery (gastric bypass) lowers mortality in diabetes and also protects the heart and kidneys, said Ms. Zuber. Overall, central obesity increases CKD risk independent of any other risk factors, but losing weight, either by surgery or diet/lifestyle, helps save the kidneys.

Cardiovascular disease is the cause of death for more than 70% of kidney disease patients, Ms. Zuber said. CKD patients “are two to three times more likely to have atrial fibrillation, so take the time to listen with that stethoscope,” she added, also emphasizing the importance of statins for all CKD and diabetes patients, and decreasing smoking. In addition, “managing metabolic acidosis slows the loss of kidney function and protects the heart.”

Additional pearls for managing chronic kidney disease include paying attention to a patient’s mental health; depression occurs in roughly 25%-47% of CKD patients, and anxiety in approximately 27%, said Ms. Zuber. Depression “is believed to be the most common psychiatric disorder in patients with end stage renal disease,” and data suggest that managing depression can help improve survival in CKD patients.

Global Academy and this news organization are owned by the same parent company. Ms. Zuber had no financial conflicts to disclose.

All patients with postpartum depression should be screened for thyroid dysfunction, as postpartum thyroiditis is often missed and misdiagnosed, according to Christine Kessler, CNS, ANP.

Postpartum thyroiditis (PPT) is “an inflammatory, autoimmune thyroid condition,” Ms. Kessler said at the Metabolic & Endocrine Disease Summit by Global Academy for Medical Education. This dysfunction can involve high or low thyroid-stimulating hormone and may occur during the first postpartum year in women who were euthyroid prior to pregnancy. Women with PPT will be thyroid peroxidase (TPO) antibody positive. Postpartum thyroiditis also can occur after a miscarriage.

PPT can occur when the immune system rebounds after pregnancy following immune suppression during pregnancy. “Autoimmune destruction of the thyroid gland leads to initial release of stored thyroid hormone,” Ms. Kessler said. Notably, “patients with a predisposition for Hashimoto’s will have an attack on the thyroid gland. Don’t miss this in your patients.”

PPT is the most common endocrine disease in premenopausal women, with an incidence of 8%-14% in the United States, noted Ms. Kessler, a nurse practitioner in private practice in Virginia. However, the symptoms are often attributed to anxiety, depression, or the stress of new motherhood.

Women with PPT have positive thyroid peroxidase antibodies, said Ms. Kessler, and the higher the antibody, the higher the risk for PPT. Other risk factors include the presence of autoimmune disorders prior to pregnancy, a patient or family history of thyroid dysfunction, and a history of PPT.

Roughly one-third of women with PPT present with hyperthyroidism alone, another third present with hypothyroidism alone, and another third have the classic presentation of PPT, which starts with a transient hyperthyroid phase that usually occurs 1-4 months post partum, followed by a hypothyroid phase and euthyroid phase that is usually achieved within the first 12-18 months post partum, she said.

Patients presenting with PPT in the hyperthyroid phase display symptoms including insomnia, anxiety, irritability, heat intolerance, fatigue, and palpitations, Ms. Kessler said. These women “are often told they have postpartum depression; they aren’t sleeping well, and they feel like they are failing as a mom.”

Patients in the hypothyroid phase may present with fatigue, depression, cold intolerance, dry skin, impaired concentration, and paresthesias, she noted.

Treatment for PPT depends on the stage patients are in when they present. For patients in the hyperthyroid phase, Ms. Kessler recommended beta-blockers for relief of symptoms including tremor and palpitations, but these should be tapered as symptoms decrease. “There is no need for antithyroid drugs for women in the hyperthyroid phase.”

For patients presenting in the hypothyroid phase, Ms. Kessler recommended levothyroxine for 6-12 months if needed, but the drug should be tapered and discontinued after PPT, as about 80% of patients will become euthyroid. However, approximately 50% of women with PPT will develop hypothyroidism in 2-10 years, so ongoing follow-up is essential for these patients.

Ms. Kessler disclosed serving as an adviser/speaker for Novo Nordisk, serving as a speaker for Salix and Acella, and serving as National Study Chair of probiotic use with antibiotics for Clarion Brand. Global Academy and this news organization are owned by the same parent company.

All patients with postpartum depression should be screened for thyroid dysfunction, as postpartum thyroiditis is often missed and misdiagnosed, according to Christine Kessler, CNS, ANP.

Postpartum thyroiditis (PPT) is “an inflammatory, autoimmune thyroid condition,” Ms. Kessler said at the Metabolic & Endocrine Disease Summit by Global Academy for Medical Education. This dysfunction can involve high or low thyroid-stimulating hormone and may occur during the first postpartum year in women who were euthyroid prior to pregnancy. Women with PPT will be thyroid peroxidase (TPO) antibody positive. Postpartum thyroiditis also can occur after a miscarriage.

PPT can occur when the immune system rebounds after pregnancy following immune suppression during pregnancy. “Autoimmune destruction of the thyroid gland leads to initial release of stored thyroid hormone,” Ms. Kessler said. Notably, “patients with a predisposition for Hashimoto’s will have an attack on the thyroid gland. Don’t miss this in your patients.”

PPT is the most common endocrine disease in premenopausal women, with an incidence of 8%-14% in the United States, noted Ms. Kessler, a nurse practitioner in private practice in Virginia. However, the symptoms are often attributed to anxiety, depression, or the stress of new motherhood.

Women with PPT have positive thyroid peroxidase antibodies, said Ms. Kessler, and the higher the antibody, the higher the risk for PPT. Other risk factors include the presence of autoimmune disorders prior to pregnancy, a patient or family history of thyroid dysfunction, and a history of PPT.

Roughly one-third of women with PPT present with hyperthyroidism alone, another third present with hypothyroidism alone, and another third have the classic presentation of PPT, which starts with a transient hyperthyroid phase that usually occurs 1-4 months post partum, followed by a hypothyroid phase and euthyroid phase that is usually achieved within the first 12-18 months post partum, she said.

Patients presenting with PPT in the hyperthyroid phase display symptoms including insomnia, anxiety, irritability, heat intolerance, fatigue, and palpitations, Ms. Kessler said. These women “are often told they have postpartum depression; they aren’t sleeping well, and they feel like they are failing as a mom.”

Patients in the hypothyroid phase may present with fatigue, depression, cold intolerance, dry skin, impaired concentration, and paresthesias, she noted.

Treatment for PPT depends on the stage patients are in when they present. For patients in the hyperthyroid phase, Ms. Kessler recommended beta-blockers for relief of symptoms including tremor and palpitations, but these should be tapered as symptoms decrease. “There is no need for antithyroid drugs for women in the hyperthyroid phase.”

For patients presenting in the hypothyroid phase, Ms. Kessler recommended levothyroxine for 6-12 months if needed, but the drug should be tapered and discontinued after PPT, as about 80% of patients will become euthyroid. However, approximately 50% of women with PPT will develop hypothyroidism in 2-10 years, so ongoing follow-up is essential for these patients.

Ms. Kessler disclosed serving as an adviser/speaker for Novo Nordisk, serving as a speaker for Salix and Acella, and serving as National Study Chair of probiotic use with antibiotics for Clarion Brand. Global Academy and this news organization are owned by the same parent company.

All patients with postpartum depression should be screened for thyroid dysfunction, as postpartum thyroiditis is often missed and misdiagnosed, according to Christine Kessler, CNS, ANP.

Postpartum thyroiditis (PPT) is “an inflammatory, autoimmune thyroid condition,” Ms. Kessler said at the Metabolic & Endocrine Disease Summit by Global Academy for Medical Education. This dysfunction can involve high or low thyroid-stimulating hormone and may occur during the first postpartum year in women who were euthyroid prior to pregnancy. Women with PPT will be thyroid peroxidase (TPO) antibody positive. Postpartum thyroiditis also can occur after a miscarriage.

PPT can occur when the immune system rebounds after pregnancy following immune suppression during pregnancy. “Autoimmune destruction of the thyroid gland leads to initial release of stored thyroid hormone,” Ms. Kessler said. Notably, “patients with a predisposition for Hashimoto’s will have an attack on the thyroid gland. Don’t miss this in your patients.”

PPT is the most common endocrine disease in premenopausal women, with an incidence of 8%-14% in the United States, noted Ms. Kessler, a nurse practitioner in private practice in Virginia. However, the symptoms are often attributed to anxiety, depression, or the stress of new motherhood.

Women with PPT have positive thyroid peroxidase antibodies, said Ms. Kessler, and the higher the antibody, the higher the risk for PPT. Other risk factors include the presence of autoimmune disorders prior to pregnancy, a patient or family history of thyroid dysfunction, and a history of PPT.

Roughly one-third of women with PPT present with hyperthyroidism alone, another third present with hypothyroidism alone, and another third have the classic presentation of PPT, which starts with a transient hyperthyroid phase that usually occurs 1-4 months post partum, followed by a hypothyroid phase and euthyroid phase that is usually achieved within the first 12-18 months post partum, she said.

Patients presenting with PPT in the hyperthyroid phase display symptoms including insomnia, anxiety, irritability, heat intolerance, fatigue, and palpitations, Ms. Kessler said. These women “are often told they have postpartum depression; they aren’t sleeping well, and they feel like they are failing as a mom.”

Patients in the hypothyroid phase may present with fatigue, depression, cold intolerance, dry skin, impaired concentration, and paresthesias, she noted.

Treatment for PPT depends on the stage patients are in when they present. For patients in the hyperthyroid phase, Ms. Kessler recommended beta-blockers for relief of symptoms including tremor and palpitations, but these should be tapered as symptoms decrease. “There is no need for antithyroid drugs for women in the hyperthyroid phase.”

For patients presenting in the hypothyroid phase, Ms. Kessler recommended levothyroxine for 6-12 months if needed, but the drug should be tapered and discontinued after PPT, as about 80% of patients will become euthyroid. However, approximately 50% of women with PPT will develop hypothyroidism in 2-10 years, so ongoing follow-up is essential for these patients.

Ms. Kessler disclosed serving as an adviser/speaker for Novo Nordisk, serving as a speaker for Salix and Acella, and serving as National Study Chair of probiotic use with antibiotics for Clarion Brand. Global Academy and this news organization are owned by the same parent company.

When there is an abnormality in the pituitary gland, many potential areas could be affected because of the extent and range of hormones produced by the “master gland,” Ashlyn Smith, PA-C, of Endocrinology Associates, Scottsdale, Ariz., said in a presentation at the at the virtual meeting of the annual Metabolic and Endocrine Disease Summit held by Global Academy for Medical Education.

The most common demographic for pituitary disorders is women in their 30s and 40s, Ms. Smith said. Early red flags for pituitary problems include patients presenting with headaches and/or blurred or double vision, which could signal bitemporal hemianopsia, she said.

Roughly two-thirds of pituitary adenomas are functional, meaning that they secrete pituitary hormones and cause clinical syndromes, Ms. Smith said. The most common reason for hypersecretion is hyperprolactinemia, she said.

Hyperprolactinemia, like most pituitary conditions, is more common in women than men, Ms. Smith noted. However, symptoms may include not only galactorrhea, but also gynecomastia, and hypogonadism, which may be red flags in men, she noted.

“Prolactin inhibits the gonadal pathway, so we see low gonadal hormones. For example, if men present with atypical hypogonadism for their age, or women present with changes in the menstrual cycle, check the prolactin levels,” she said.

The etiologies of hyperprolactinemia include physiologic reasons such as breastfeeding and pregnancy, as well as intercourse and breast manipulation, stress, and sleep issues. Pathologic reasons for prolactin elevation include prolactinoma, gonad-hormone secreting tumor, hypothyroidism, and renal insufficiency, Ms. Smith said.

Evaluation of patients with suspected hyperprolactinemia includes screening for physiologic causes, renal function and thyroid function tests, and a thyroid-specific MRI. Ordering a dedicated MRI of the pituitary gland is important to help identify compression of the optic nerve, noted Ms. Smith.

A medication review also is essential in evaluating hyperprolactinemia, and especially in the setting of the COVID-19 pandemic, because patients may have made changes to psychiatric medications, said Ms. Smith. Neuroleptics and antipsychotics including risperidone, haloperidol, chlorpromazine, and thiothixene can be associated with hyperprolactinemia, as can benzodiazepines and various analgesics and antidepressants, she said.

Treatment in cases of medication-induced hyperprolactinemia can be challenging if the patients are unable to change a medication, said Ms. Smith. However, patients with hypogonadism or low bone mineral density who can’t change medications may benefit from exogenous gonadal hormones, she said.

Some patients with hyperprolactinemia benefit from treatment with dopamine agonists, which may ease symptoms and reduce the size of the prolactinoma, she explained. However, patients on dopamine agonists should be alert to side effects including constipation and orthostasis. Ms. Smith said she recommends that patients on dopamine agonists for hyperprolactinemia take the medication at night so they are lying down if orthostasis occurs.

Monitor prolactin levels at 1 month, and taper or discontinue if the prolactin returns to normal and the adenoma resolves, which can take approximately 2 years, she said. Ms. Smith then advised follow-up every 3 months for 1 year, then annual prolactin checks.

The risk of recurrence ranges from 26% to 69%, Ms. Smith said, and is higher in patients with higher prolactin levels and larger adenomas, she noted. Recurrence is most likely within a year of withdrawal from treatment, she said.

Ms. Smith disclosed serving as an adviser and speaker for Abbott Nutrition, a speaker for Xeris Pharmaceuticals, and an adviser for Sanofi and Radius.

Global Academy for Medical Education and this news organization are owned by the same parent company.

SOURCE: Smith A. MEDS 2020.

When there is an abnormality in the pituitary gland, many potential areas could be affected because of the extent and range of hormones produced by the “master gland,” Ashlyn Smith, PA-C, of Endocrinology Associates, Scottsdale, Ariz., said in a presentation at the at the virtual meeting of the annual Metabolic and Endocrine Disease Summit held by Global Academy for Medical Education.

The most common demographic for pituitary disorders is women in their 30s and 40s, Ms. Smith said. Early red flags for pituitary problems include patients presenting with headaches and/or blurred or double vision, which could signal bitemporal hemianopsia, she said.

Roughly two-thirds of pituitary adenomas are functional, meaning that they secrete pituitary hormones and cause clinical syndromes, Ms. Smith said. The most common reason for hypersecretion is hyperprolactinemia, she said.

Hyperprolactinemia, like most pituitary conditions, is more common in women than men, Ms. Smith noted. However, symptoms may include not only galactorrhea, but also gynecomastia, and hypogonadism, which may be red flags in men, she noted.

“Prolactin inhibits the gonadal pathway, so we see low gonadal hormones. For example, if men present with atypical hypogonadism for their age, or women present with changes in the menstrual cycle, check the prolactin levels,” she said.

The etiologies of hyperprolactinemia include physiologic reasons such as breastfeeding and pregnancy, as well as intercourse and breast manipulation, stress, and sleep issues. Pathologic reasons for prolactin elevation include prolactinoma, gonad-hormone secreting tumor, hypothyroidism, and renal insufficiency, Ms. Smith said.

Evaluation of patients with suspected hyperprolactinemia includes screening for physiologic causes, renal function and thyroid function tests, and a thyroid-specific MRI. Ordering a dedicated MRI of the pituitary gland is important to help identify compression of the optic nerve, noted Ms. Smith.

A medication review also is essential in evaluating hyperprolactinemia, and especially in the setting of the COVID-19 pandemic, because patients may have made changes to psychiatric medications, said Ms. Smith. Neuroleptics and antipsychotics including risperidone, haloperidol, chlorpromazine, and thiothixene can be associated with hyperprolactinemia, as can benzodiazepines and various analgesics and antidepressants, she said.

Treatment in cases of medication-induced hyperprolactinemia can be challenging if the patients are unable to change a medication, said Ms. Smith. However, patients with hypogonadism or low bone mineral density who can’t change medications may benefit from exogenous gonadal hormones, she said.

Some patients with hyperprolactinemia benefit from treatment with dopamine agonists, which may ease symptoms and reduce the size of the prolactinoma, she explained. However, patients on dopamine agonists should be alert to side effects including constipation and orthostasis. Ms. Smith said she recommends that patients on dopamine agonists for hyperprolactinemia take the medication at night so they are lying down if orthostasis occurs.

Monitor prolactin levels at 1 month, and taper or discontinue if the prolactin returns to normal and the adenoma resolves, which can take approximately 2 years, she said. Ms. Smith then advised follow-up every 3 months for 1 year, then annual prolactin checks.

The risk of recurrence ranges from 26% to 69%, Ms. Smith said, and is higher in patients with higher prolactin levels and larger adenomas, she noted. Recurrence is most likely within a year of withdrawal from treatment, she said.

Ms. Smith disclosed serving as an adviser and speaker for Abbott Nutrition, a speaker for Xeris Pharmaceuticals, and an adviser for Sanofi and Radius.

Global Academy for Medical Education and this news organization are owned by the same parent company.

SOURCE: Smith A. MEDS 2020.

When there is an abnormality in the pituitary gland, many potential areas could be affected because of the extent and range of hormones produced by the “master gland,” Ashlyn Smith, PA-C, of Endocrinology Associates, Scottsdale, Ariz., said in a presentation at the at the virtual meeting of the annual Metabolic and Endocrine Disease Summit held by Global Academy for Medical Education.

The most common demographic for pituitary disorders is women in their 30s and 40s, Ms. Smith said. Early red flags for pituitary problems include patients presenting with headaches and/or blurred or double vision, which could signal bitemporal hemianopsia, she said.

Roughly two-thirds of pituitary adenomas are functional, meaning that they secrete pituitary hormones and cause clinical syndromes, Ms. Smith said. The most common reason for hypersecretion is hyperprolactinemia, she said.

Hyperprolactinemia, like most pituitary conditions, is more common in women than men, Ms. Smith noted. However, symptoms may include not only galactorrhea, but also gynecomastia, and hypogonadism, which may be red flags in men, she noted.

“Prolactin inhibits the gonadal pathway, so we see low gonadal hormones. For example, if men present with atypical hypogonadism for their age, or women present with changes in the menstrual cycle, check the prolactin levels,” she said.

The etiologies of hyperprolactinemia include physiologic reasons such as breastfeeding and pregnancy, as well as intercourse and breast manipulation, stress, and sleep issues. Pathologic reasons for prolactin elevation include prolactinoma, gonad-hormone secreting tumor, hypothyroidism, and renal insufficiency, Ms. Smith said.

Evaluation of patients with suspected hyperprolactinemia includes screening for physiologic causes, renal function and thyroid function tests, and a thyroid-specific MRI. Ordering a dedicated MRI of the pituitary gland is important to help identify compression of the optic nerve, noted Ms. Smith.

A medication review also is essential in evaluating hyperprolactinemia, and especially in the setting of the COVID-19 pandemic, because patients may have made changes to psychiatric medications, said Ms. Smith. Neuroleptics and antipsychotics including risperidone, haloperidol, chlorpromazine, and thiothixene can be associated with hyperprolactinemia, as can benzodiazepines and various analgesics and antidepressants, she said.

Treatment in cases of medication-induced hyperprolactinemia can be challenging if the patients are unable to change a medication, said Ms. Smith. However, patients with hypogonadism or low bone mineral density who can’t change medications may benefit from exogenous gonadal hormones, she said.

Some patients with hyperprolactinemia benefit from treatment with dopamine agonists, which may ease symptoms and reduce the size of the prolactinoma, she explained. However, patients on dopamine agonists should be alert to side effects including constipation and orthostasis. Ms. Smith said she recommends that patients on dopamine agonists for hyperprolactinemia take the medication at night so they are lying down if orthostasis occurs.

Monitor prolactin levels at 1 month, and taper or discontinue if the prolactin returns to normal and the adenoma resolves, which can take approximately 2 years, she said. Ms. Smith then advised follow-up every 3 months for 1 year, then annual prolactin checks.

The risk of recurrence ranges from 26% to 69%, Ms. Smith said, and is higher in patients with higher prolactin levels and larger adenomas, she noted. Recurrence is most likely within a year of withdrawal from treatment, she said.

Ms. Smith disclosed serving as an adviser and speaker for Abbott Nutrition, a speaker for Xeris Pharmaceuticals, and an adviser for Sanofi and Radius.

Global Academy for Medical Education and this news organization are owned by the same parent company.

SOURCE: Smith A. MEDS 2020.

Updated assessment and treatment options provide more tools to help clinicians manage osteoporosis and reduce fracture risk, according to Rick Pope, MPAS, PA-C.

iStock/Thinkstock

Criteria from the National Osteoporosis Foundation for the diagnosis of osteoporosis expanded in 2020 to include a T score measure of –2.5 or less at the wrist in postmenopausal women or in men aged 50 years and older (in addition to existing criteria of –2.5 or lower T scores at the lumbar spine, femoral neck, or total hip), he said in a presentation at the virtual annual Metabolic and Endocrine Disease Summit by Global Academy for Medical Education.

Other updated diagnostic criteria for osteoporosis include a low-trauma hip fracture regardless of bone mineral density, and a history of fracture of the pelvis or wrist in the context of osteopenia (in addition to the existing criteria of fracture of the vertebrae or proximal humerus).

When a diagnosis of osteoporosis is established, the Fracture Risk Assessment Tool calculator continues to serve as useful tool that allows clinicians to easily input patient data and obtain a projection of fracture risk, Mr. Pope said.

During a clinical visit, be sure to measure patients’ height, and look for kyphosis to help evaluate fall risk. Progressive kyphosis is important because the head weight can increase to 40 pounds if the kyphosis progresses to 30 degrees, and puts further stress on the vertebrae, he emphasized. In addition, looking at gait is important, especially for older patients, said Mr. Pope. “I want to get an assessment of how steady they are on their feet.”

Vertebral fracture assessment (VFA) is a useful strategy to evaluate the spine for silent compression fractures, especially in someone who has lost 1.5 inches in height or is on chronic steroids, Mr. Pope said. VFA has several advantages, including lower cost and lower radiation exposure than plain radiographs of the spine.

In addition, trabecular bone score (TBS) allows clinicians to evaluate bone microarchitecture, and this score can serve as an important indicator of fracture risk, Mr. Pope said.

As for treatment options, managing skeletal health in osteoporosis patients includes advising patients on healthy lifestyle practices that include not only adequate calcium and vitamin D, but also smoking cessation and a combination of weight-bearing, dynamic balance, and resistive exercises, he noted.

When considering medications, patient factors determine the most appropriate drug to use, Mr. Pope emphasized.

Bisphosphonates remain an option for treatment and have shown effectiveness at reducing fracture risk in postmenopausal women with osteoporosis, but concerns persist about side effects such as osteonecrosis of the jaw and atypical femoral fractures (AFF), he noted.

Reassure patients that AFF is more of an issue with long-term bisphosphonate use, Mr. Pope said, citing a 2012 study in which the risk of atypical femoral fracture was 1.78 per 100,000 person-years among individuals with 0.1-1.9 years of bisphosphonate exposure, but this jumped to 113 per 100,000 person-years among those with 8-9.9 years of bisphosphonate exposure.

“Eight years seems to be the sweet spot,” before a significant increase, he said. In his clinic, clinicians stop patients at about 8 years of bisphosphonate treatment, and then consider restarting.

However, nonbisphosphonate treatments are also available, including the monoclonal antibody denosumab. “It is different than bisphosphonates, and the effect wears off rapidly,” said Mr. Pope. Also, creatinine clearance is not an issue with denosumab. However, when patients have gone past the 10-year mark, should be switched to an alternative treatment because of an increased fracture risk at that point.

One relatively new treatment, abaloparatide, is currently indicated only for postmenopausal women with osteoporosis. Data have shown an 86% reduction in vertebral fracture risk, but the drug carries a black-box warning for osteosarcoma, said Mr. Pope.

Romosozumab, another newcomer drug, is indicated only for postmenopausal osteoporotic women at high risk for fracture with multiple risk factors who have failed other therapies. Romosozumab carries a black-box warning for cardiovascular risk for those with a history of MI or stroke. “This is a completely different mechanism of action” from other drugs, Mr. Pope said. The drug is given twice a month for a total of 12 months, and must be administered by a health professional in an office setting.

Mr. Pope had no financial conflicts to disclose. Global Academy for Medical Education and this news organization are owned by the same parent company.

Updated assessment and treatment options provide more tools to help clinicians manage osteoporosis and reduce fracture risk, according to Rick Pope, MPAS, PA-C.

iStock/Thinkstock

Criteria from the National Osteoporosis Foundation for the diagnosis of osteoporosis expanded in 2020 to include a T score measure of –2.5 or less at the wrist in postmenopausal women or in men aged 50 years and older (in addition to existing criteria of –2.5 or lower T scores at the lumbar spine, femoral neck, or total hip), he said in a presentation at the virtual annual Metabolic and Endocrine Disease Summit by Global Academy for Medical Education.

Other updated diagnostic criteria for osteoporosis include a low-trauma hip fracture regardless of bone mineral density, and a history of fracture of the pelvis or wrist in the context of osteopenia (in addition to the existing criteria of fracture of the vertebrae or proximal humerus).

When a diagnosis of osteoporosis is established, the Fracture Risk Assessment Tool calculator continues to serve as useful tool that allows clinicians to easily input patient data and obtain a projection of fracture risk, Mr. Pope said.

During a clinical visit, be sure to measure patients’ height, and look for kyphosis to help evaluate fall risk. Progressive kyphosis is important because the head weight can increase to 40 pounds if the kyphosis progresses to 30 degrees, and puts further stress on the vertebrae, he emphasized. In addition, looking at gait is important, especially for older patients, said Mr. Pope. “I want to get an assessment of how steady they are on their feet.”

Vertebral fracture assessment (VFA) is a useful strategy to evaluate the spine for silent compression fractures, especially in someone who has lost 1.5 inches in height or is on chronic steroids, Mr. Pope said. VFA has several advantages, including lower cost and lower radiation exposure than plain radiographs of the spine.

In addition, trabecular bone score (TBS) allows clinicians to evaluate bone microarchitecture, and this score can serve as an important indicator of fracture risk, Mr. Pope said.

As for treatment options, managing skeletal health in osteoporosis patients includes advising patients on healthy lifestyle practices that include not only adequate calcium and vitamin D, but also smoking cessation and a combination of weight-bearing, dynamic balance, and resistive exercises, he noted.

When considering medications, patient factors determine the most appropriate drug to use, Mr. Pope emphasized.

Bisphosphonates remain an option for treatment and have shown effectiveness at reducing fracture risk in postmenopausal women with osteoporosis, but concerns persist about side effects such as osteonecrosis of the jaw and atypical femoral fractures (AFF), he noted.

Reassure patients that AFF is more of an issue with long-term bisphosphonate use, Mr. Pope said, citing a 2012 study in which the risk of atypical femoral fracture was 1.78 per 100,000 person-years among individuals with 0.1-1.9 years of bisphosphonate exposure, but this jumped to 113 per 100,000 person-years among those with 8-9.9 years of bisphosphonate exposure.

“Eight years seems to be the sweet spot,” before a significant increase, he said. In his clinic, clinicians stop patients at about 8 years of bisphosphonate treatment, and then consider restarting.

However, nonbisphosphonate treatments are also available, including the monoclonal antibody denosumab. “It is different than bisphosphonates, and the effect wears off rapidly,” said Mr. Pope. Also, creatinine clearance is not an issue with denosumab. However, when patients have gone past the 10-year mark, should be switched to an alternative treatment because of an increased fracture risk at that point.

One relatively new treatment, abaloparatide, is currently indicated only for postmenopausal women with osteoporosis. Data have shown an 86% reduction in vertebral fracture risk, but the drug carries a black-box warning for osteosarcoma, said Mr. Pope.

Romosozumab, another newcomer drug, is indicated only for postmenopausal osteoporotic women at high risk for fracture with multiple risk factors who have failed other therapies. Romosozumab carries a black-box warning for cardiovascular risk for those with a history of MI or stroke. “This is a completely different mechanism of action” from other drugs, Mr. Pope said. The drug is given twice a month for a total of 12 months, and must be administered by a health professional in an office setting.

Mr. Pope had no financial conflicts to disclose. Global Academy for Medical Education and this news organization are owned by the same parent company.

Updated assessment and treatment options provide more tools to help clinicians manage osteoporosis and reduce fracture risk, according to Rick Pope, MPAS, PA-C.

iStock/Thinkstock

Criteria from the National Osteoporosis Foundation for the diagnosis of osteoporosis expanded in 2020 to include a T score measure of –2.5 or less at the wrist in postmenopausal women or in men aged 50 years and older (in addition to existing criteria of –2.5 or lower T scores at the lumbar spine, femoral neck, or total hip), he said in a presentation at the virtual annual Metabolic and Endocrine Disease Summit by Global Academy for Medical Education.

Other updated diagnostic criteria for osteoporosis include a low-trauma hip fracture regardless of bone mineral density, and a history of fracture of the pelvis or wrist in the context of osteopenia (in addition to the existing criteria of fracture of the vertebrae or proximal humerus).

When a diagnosis of osteoporosis is established, the Fracture Risk Assessment Tool calculator continues to serve as useful tool that allows clinicians to easily input patient data and obtain a projection of fracture risk, Mr. Pope said.

During a clinical visit, be sure to measure patients’ height, and look for kyphosis to help evaluate fall risk. Progressive kyphosis is important because the head weight can increase to 40 pounds if the kyphosis progresses to 30 degrees, and puts further stress on the vertebrae, he emphasized. In addition, looking at gait is important, especially for older patients, said Mr. Pope. “I want to get an assessment of how steady they are on their feet.”

Vertebral fracture assessment (VFA) is a useful strategy to evaluate the spine for silent compression fractures, especially in someone who has lost 1.5 inches in height or is on chronic steroids, Mr. Pope said. VFA has several advantages, including lower cost and lower radiation exposure than plain radiographs of the spine.

In addition, trabecular bone score (TBS) allows clinicians to evaluate bone microarchitecture, and this score can serve as an important indicator of fracture risk, Mr. Pope said.

As for treatment options, managing skeletal health in osteoporosis patients includes advising patients on healthy lifestyle practices that include not only adequate calcium and vitamin D, but also smoking cessation and a combination of weight-bearing, dynamic balance, and resistive exercises, he noted.

When considering medications, patient factors determine the most appropriate drug to use, Mr. Pope emphasized.

Bisphosphonates remain an option for treatment and have shown effectiveness at reducing fracture risk in postmenopausal women with osteoporosis, but concerns persist about side effects such as osteonecrosis of the jaw and atypical femoral fractures (AFF), he noted.

Reassure patients that AFF is more of an issue with long-term bisphosphonate use, Mr. Pope said, citing a 2012 study in which the risk of atypical femoral fracture was 1.78 per 100,000 person-years among individuals with 0.1-1.9 years of bisphosphonate exposure, but this jumped to 113 per 100,000 person-years among those with 8-9.9 years of bisphosphonate exposure.

“Eight years seems to be the sweet spot,” before a significant increase, he said. In his clinic, clinicians stop patients at about 8 years of bisphosphonate treatment, and then consider restarting.

However, nonbisphosphonate treatments are also available, including the monoclonal antibody denosumab. “It is different than bisphosphonates, and the effect wears off rapidly,” said Mr. Pope. Also, creatinine clearance is not an issue with denosumab. However, when patients have gone past the 10-year mark, should be switched to an alternative treatment because of an increased fracture risk at that point.

One relatively new treatment, abaloparatide, is currently indicated only for postmenopausal women with osteoporosis. Data have shown an 86% reduction in vertebral fracture risk, but the drug carries a black-box warning for osteosarcoma, said Mr. Pope.

Romosozumab, another newcomer drug, is indicated only for postmenopausal osteoporotic women at high risk for fracture with multiple risk factors who have failed other therapies. Romosozumab carries a black-box warning for cardiovascular risk for those with a history of MI or stroke. “This is a completely different mechanism of action” from other drugs, Mr. Pope said. The drug is given twice a month for a total of 12 months, and must be administered by a health professional in an office setting.

Mr. Pope had no financial conflicts to disclose. Global Academy for Medical Education and this news organization are owned by the same parent company.